PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Negative EBIT growth while AVXL is at 12.32%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-30.79%
Negative operating income growth while AVXL is at 12.32%. Joel Greenblatt would press for urgent turnaround measures.
-31.28%
Negative net income growth while AVXL stands at 11.66%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-21.00%
Negative EPS growth while AVXL is at 17.65%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.22%
Negative diluted EPS growth while AVXL is at 17.65%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.78%
Share count expansion well above AVXL's 5.28%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.68%
Diluted share count expanding well above AVXL's 5.28%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-4.24%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Negative 10Y OCF/share CAGR while AVXL stands at 35.56%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
76.96%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
70.68%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-11609.25%
Negative 10Y net income/share CAGR while AVXL is at 46.40%. Joel Greenblatt sees a major red flag in long-term profit erosion.
81.05%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
70.82%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
881.79%
10Y equity/share CAGR above 1.5x AVXL's 166.16%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-26.92%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-79.64%
Negative 3Y equity/share growth while AVXL is at 65.40%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Negative asset growth while AVXL invests at 6.90%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-41.29%
We have a declining book value while AVXL shows 18.11%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-11.75%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
20.45%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
69.30%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.